These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20976259)

  • 1. Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines.
    Zhou J; Oliveira P; Li X; Chen Z; Bepler G
    J Nucleic Acids; 2010 Sep; 2010():597098. PubMed ID: 20976259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.
    Reid G; Wallant NC; Patel R; Antonic A; Saxon-Aliifaalogo F; Cao H; Webster G; Watson JD
    J RNAi Gene Silencing; 2009 Mar; 5(1):321-30. PubMed ID: 19771229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
    Sagawa M; Ohguchi H; Harada T; Samur MK; Tai YT; Munshi NC; Kizaki M; Hideshima T; Anderson KC
    Clin Cancer Res; 2017 Sep; 23(17):5225-5237. PubMed ID: 28442502
    [No Abstract]   [Full Text] [Related]  

  • 5. Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
    Wakai T; Shirai Y; Sakata J; Takamura M; Matsuda Y; Korita PV; Muneoka K; Sasaki M; Ajioka Y; Hatakeyama K
    Hepatogastroenterology; 2011; 58(110-111):1659-63. PubMed ID: 21940346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
    Deng T; Pan H; Han R; Huang D; Li H; Zhou L; Wang X; Bai M; Li X; Liu R; Ge S; Ning T; Zhang L; Ba Y
    Int J Clin Exp Med; 2014; 7(12):5041-9. PubMed ID: 25664003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.
    Volante M; Terzolo M; Fassnacht M; Rapa I; Germano A; Sbiera S; Daffara F; Sperone P; Scagliotti G; Allolio B; Papotti M; Berruti A
    Clin Cancer Res; 2012 Jun; 18(12):3452-61. PubMed ID: 22547773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Lee JJ; Maeng CH; Baek SK; Kim GY; Yoo JH; Choi CW; Kim YH; Kwak YT; Kim DH; Lee YK; Kim JB; Kim SY
    Lung Cancer; 2010 Nov; 70(2):205-10. PubMed ID: 20223551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine.
    Aoyama T; Miyagi Y; Murakawa M; Yamaoku K; Atsumi Y; Shiozawa M; Ueno M; Morimoto M; Oshima T; Yukawa N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Oncol Lett; 2017 May; 13(5):3423-3430. PubMed ID: 28521448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
    J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].
    Tian N; Zhou L; Yang D; Wu H; Ma Y; Lü L; Wu S
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):304-312. PubMed ID: 31068300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
    Zimling ZG; Santoni-Rugiu E; Bech C; Sørensen JB
    Anticancer Res; 2015 Dec; 35(12):6731-8. PubMed ID: 26637889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis.
    Zhu CM; Lian XY; Bi YH; Hu CC; Liang YW; Li QS
    Clin Chim Acta; 2018 Oct; 485():67-73. PubMed ID: 29803896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
    Jordheim LP; Sève P; Trédan O; Dumontet C
    Lancet Oncol; 2011 Jul; 12(7):693-702. PubMed ID: 21163702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase large subunit M1 plays a different role in the invasion and metastasis of papillary thyroid carcinoma and undifferentiated thyroid carcinoma.
    Fang Z; Song R; Gong C; Zhang X; Ren G; Li J; Chen Y; Qiu L; Mei L; Zhang R; Xiang X; Chen X; Shao J
    Tumour Biol; 2016 Mar; 37(3):3515-26. PubMed ID: 26453115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y; Chen L; Li J; Lü YL; Jiao SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization.
    Germano A; Rapa I; Volante M; De Francia S; Migliore C; Berruti A; Papotti M; Terzolo M
    Mol Cell Endocrinol; 2015 Feb; 401():105-10. PubMed ID: 25497672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells.
    Yi YW; Park NY; Park JI; Seong YS; Hong YB
    Am J Cancer Res; 2021; 11(7):3515-3536. PubMed ID: 34354858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study.
    Imai H; Saijo K; Komine K; Otsuki Y; Ohuchi K; Sato Y; Okita A; Takahashi M; Takahashi S; Shirota H; Takahashi M; Ishioka C
    Cancer Manag Res; 2019; 11():7953-7965. PubMed ID: 31686910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.